<h1>Albert David Limited Approves Appointment and Tenure of Mr. Amit Mahla as Whole-time Director & CEO</h1>
Board approval at Albert David Limited has formalized the role of Mr. Amit Mahla, expanding his responsibilities within the company structure. At its meeting held on June 19, 2026, the Board of Directors approved the appointment of Mr. Amit Mahla as an Additional Director and granted him the position of Whole-time Director & CEO of Albert David Limited.
The appointments were made based on recommendations from the Nomination and Remuneration Committee and the Audit Committee. Mr. Mahla was previously appointed as CEO effective May 12, 2026. The Board approved his tenure as Whole-time Director & CEO for a period of five years, commencing June 19, 2026, and concluding on June 18, 2031.
The company fixed the remuneration for Mr. Mahla covering the period from June 19, 2026, to March 31, 2027. These appointments are subject to the approval of shareholders at the 87th Annual General Meeting (AGM).
| Role | Appointment Date | Term Duration | Status Condition |
|---|---|---|---|
| Additional Director | June 19, 2026 | Until 87th AGM | Subject to shareholder approval at the 87th AGM |
| Whole-time Director & CEO | June 19, 2026 | 5 Years (until June 18, 2031) | Subject to shareholder approval at the 87th AGM |
The Board also revised the Notice of the 87th AGM. The updated notice now includes matters requiring shareholders' approval regarding the regularisation and appointment of Mr. Amit Mahla as Whole-time Director & CEO, along with the fixation of his remuneration.
Experienced Leadership Profile
Mr. Amit Mahla is described as a seasoned leader with over 28 years of experience in the industry. He holds a degree in Science, a postgraduate degree in English Literature, and an Executive MBA (Rank Holder) from SIES, Mumbai.His professional background includes leadership roles across several prominent organizations such as Cipla, Emcure, Glenmark, Alembic, Sun Pharma, and JB Pharma. Mr. Mahla brings extensive expertise across both acute and chronic segments of the Indian Pharmaceutical Market (IPM). His experience also encompasses entrepreneurial leadership in Innovcare life sciences.
During his tenure with JB Pharma, he was instrumental in managing the integration of Sanzyme into the company, which is noted as one of the most significant acquisitions in the IPM recently. Mr. Mahla has a proven track record of transforming underperforming businesses and possesses expertise in strategic leadership, new product launches, and creating new business categories.
Regarding director relationships, Mr. Amit Mahla is not related to any other directors or key managerial personnel of the Company. Furthermore, he is not debarred from holding the office of Director by any order of SEBI or any other relevant authority.
ALBERTDAVD Stock Price Movement
Today, Albert David Limited shares edged up to settle at ₹711.15 after posting a 0.91% gain in the market close. The stock traded within a narrow intraday band, hitting a low of ₹710 and climbing as high as ₹719.9 during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.